share_log

天壇生物(600161.SH)研製全球首款新冠肺炎「特效藥」獲批臨床試驗

Tiantan Biological (600161.SH) to develop the world's first COVID-19 "specific drug" approved clinical trial

即市頭條 ·  Sep 6, 2021 07:49

The intravenous injection of COVID-19 human immunoglobulin (pH4) developed by Tiantan Bio (600161.SH), a Chinese biological blood products plate enterprise of Sinopharmaceutical Group, has recently been approved to carry out clinical trials by the Drug Clinical trial approval issued by the State Drug Administration.

Intravenous injection of COVID-19 human immunoglobulin (pH4) is a kind of new drug for therapeutic biology. it is the first specific therapeutic drug prepared by COVID-19 after being immunized with new crown inactivated vaccine in the world.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment